FDA advisers raised concerns regarding the efficacy and risk-benefit profile of Genentech’s Polivy as a first-line treatment for large B-cell lymphoma ahead of a March 9 advisory committee meeting.
https://www.pharmalive.com/wp-content/uploads/2021/06/Roche-Presents-Positive-Clinical-Data-for-Neurology-Programs-at-EAN-Annual-Meeting-BioSpace-6-22-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-03-08 10:39:052023-03-08 10:39:25FDA advisers question efficacy of Roche’s Polivy in first line LBCL
